Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Pneumococcal vaccination strategies in adults with underlying medical and social conditions at high risk for invasive disease: a population-based study assessing disease burden and effective interventions to improve equity and access
EF 2023-24
Résumé
Pneumococcal infection is caused by the Streptococcus pneumoniae bacteria, which can cause severe and life-threatening infections such as meningitis, an infection of the lining covering the brain; septicemia, an infection of the blood; and pneumonia, an infection of the lungs. Anyone can get pneumococcal disease, but children under two years of age, adults 65 years or older, and people with certain medical and social conditions are at the highest risk. Social determinants such as not having housing or cigarette smoking also increase the risk of invasive disease after infection. Immunization has saved more lives in Canada in the last 50 years than any other health measure. To protect individuals from pneumococcal disease, publicly funded pneumococcal immunizations are available for young children two years of age or less and older adults 65 years old or over, as well as high risk individuals between the ages of 50 to 64. Recently, new vaccines have become available for the prevention of invasive pneumococcal disease in adults, but the burden of disease that may be reduced with the new products is unknown for people with underlying medical conditions or high risk lifestyles. In this study, we will use large healthcare databases from British Columbia to understand how often adults 18 to 49 with underlying medical or social conditions get pneumococcal infections. Given the risks of infection and differences in public funding of vaccines across provinces for this age group, we will also determine opportunities for equity-informed vaccination strategies. Our research findings will help decision-makers to make evidence-based vaccination recommendations and shape healthcare policy to reduce Canada's pneumococcal disease burden and advance our national healthy aging strategy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505913
Name
Chang Chia-Yuan
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pneumococcal vaccination strategies in adults with underlying medical and social conditions at high risk for invasive disease: a population-based study assessing disease burden and effective interventions to improve equity and access
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Diseases; Effectiveness; Health Policy; Immunization; Invasive Pneumococcal Disease; Pneumococcal Vaccines; Pneumococcus; Safety; Streptococcus Pneumoniae; Vaccination Policy
Abstract
Pneumococcal infection is caused by the Streptococcus pneumoniae bacteria, which can cause severe and life-threatening infections such as meningitis, an infection of the lining covering the brain; septicemia, an infection of the blood; and pneumonia, an infection of the lungs. Anyone can get pneumococcal disease, but children under two years of age, adults 65 years or older, and people with certain medical and social conditions are at the highest risk. Social determinants such as not having housing or cigarette smoking also increase the risk of invasive disease after infection. Immunization has saved more lives in Canada in the last 50 years than any other health measure. To protect individuals from pneumococcal disease, publicly funded pneumococcal immunizations are available for young children two years of age or less and older adults 65 years old or over, as well as high risk individuals between the ages of 50 to 64. Recently, new vaccines have become available for the prevention of invasive pneumococcal disease in adults, but the burden of disease that may be reduced with the new products is unknown for people with underlying medical conditions or high risk lifestyles. In this study, we will use large healthcare databases from British Columbia to understand how often adults 18 to 49 with underlying medical or social conditions get pneumococcal infections. Given the risks of infection and differences in public funding of vaccines across provinces for this age group, we will also determine opportunities for equity-informed vaccination strategies. Our research findings will help decision-makers to make evidence-based vaccination recommendations and shape healthcare policy to reduce Canada's pneumococcal disease burden and advance our national healthy aging strategy.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chang, Chia-Yuan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~